Doxorubicin and Edelfosine Combo-Loaded Lipid–Polymer Hybrid Nanoparticles for Synergistic Anticancer Effect Against Drug-Resistant Osteosarcoma [Retraction]
OncoTargets and Therapy · 2026-04 · Volume 19 · 1-1
DOI: 10.2147/ott.s614697 ↗Kurz gefasst
Fachartikel in der Zeitschrift OncoTargets and Therapy, 2026-04. Verfasst von Ping Yang und 7 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Yang, P., Zhang, L., Wang, T., Liu, Q., Wang, J., Wang, Y., Tu, Z., & Lin, F. (2026). Doxorubicin and Edelfosine Combo-Loaded Lipid–Polymer Hybrid Nanoparticles for Synergistic Anticancer Effect Against Drug-Resistant Osteosarcoma [Retraction]. OncoTargets and Therapy, Volume 19, 1-1. https://doi.org/10.2147/ott.s614697
Vancouver
Yang P, Zhang L, Wang T, Liu Q, Wang J, Wang Y, et al. Doxorubicin and Edelfosine Combo-Loaded Lipid–Polymer Hybrid Nanoparticles for Synergistic Anticancer Effect Against Drug-Resistant Osteosarcoma [Retraction]. OncoTargets and Therapy. 2026;Volume 19:1-1. doi:10.2147/ott.s614697
BibTeX
@article{Yang2026,
author = {Yang, Ping and Zhang, Lian and Wang, Tian and Liu, Qi and Wang, Jing and Wang, Yaling and Tu, Zhiquan and Lin, Feng},
title = {Doxorubicin and Edelfosine Combo-Loaded Lipid–Polymer Hybrid Nanoparticles for Synergistic Anticancer Effect Against Drug-Resistant Osteosarcoma [Retraction]},
journal = {OncoTargets and Therapy},
year = {2026},
volume = {Volume 19},
pages = {1--1},
doi = {10.2147/ott.s614697}
}
EUVIMED